Schizophrenia

Insight Linked to Meds Adherence in Schizophrenia

Insight Linked to Meds Adherence in Schizophrenia – MM1603

The first episode of a psychotic disorder typically occurs in late adolescence
or young adulthood, a critical time of development with respect to personality,
social role, education, and vocation. The first few years of psychosis appear to
be a critical period during which intervention needs to be initiated before the
consequences of psychosis become more severe. Early intervention is therefore
crucial in maximising outcomes.

Medication attitudes, insight and characteristics of support have been
identified as important determinants of adherence to medication,2 with poor
insight being linked to poor outcome of psychosis in multiple ways. The negative influence of poor insight has been demonstrated in relation to quality of life, rehospitalisation, poor treatment adherence and poor outcome of psychosis

Modern Medicine – March 2016

March 18, 2016 by Psychiatry Schizophrenia

Olanzapine for Schizophrenia Improves Meds Compliance

Olanzapine for Schizophrenia Improves Meds Compliance – MM1510

Schizophrenia is a chronic and disabling psychiatric disorder afflicting approximately one percent of the population world-wide with little gender differences. For patients with schizophrenia, treatment with antipsychotics is typically necessary for the long term, but persistence on treatment is often poor, resulting in frequent relapses with potentially serious consequences.

Modern Medicine – October 2015

 

October 27, 2015 by CNS Schizophrenia

The Treatment of Schizophrenia An Overlooked ‘Duty to Care’

The Treatment of Schizophrenia An Overlooked ‘Duty to Care’ – MM1506

Schizophrenia remains a challenging illness causing high levels of chronic disability. Identifying the condition early is difficult, medication adherence is problematic, the availability of psychosocial interventions is limited and the poor physical health of people with schizophrenia is often overlooked.

Modern Medicine – June 2015

June 23, 2015 by CNS Psychiatry Schizophrenia

Schizophrenia is at Least Partly a Inflammatory Response

Schizophrenia is at Least Partly a Inflammatory Response – MM1501

Schizophrenia (SZ) is a complex, heterogeneous disease characterised by psychosis, affecting approximately 1% of the population. Core negative symptoms of SZ include cognitive deficits, social avoidance and flat affect; positive symptoms include paranoia, hyperactivity and psychosis. Linkage analyses reflect a high impact of genetics on incidence of SZ, although environmental effects such as life events and prenatal and early development may contribute to the disease.

Modern Medicine – January 2015

January 27, 2015 by Neurology Schizophrenia
Verified by ExactMetrics